Synaptogenix (SNPX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Key Stats

• Today's Range: $8.10 to $9.31
• 50-Day Range: $3.48 to $10.38
• 52-Week Range: $1.84 to $7.85
• Volume: 249,702 shs
• Average Volume: 250,819 shs
• Market Capitalization: $11.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNPX Stock Analysis - Frequently Asked Questions

How have SNPX shares performed this year?

Synaptogenix's stock was trading at $3.47 at the start of the year. Since then, SNPX shares have increased by 142.1% and is now trading at $8.40.

How were Synaptogenix's earnings last quarter?

Synaptogenix, Inc. (NASDAQ:SNPX) announced its quarterly earnings results on Thursday, May, 15th. The company reported $0.04 EPS for the quarter.

When did Synaptogenix's stock split?

Shares of Synaptogenix reverse split before market open on Friday, April 5th 2024.The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Synaptogenix?

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synaptogenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synaptogenix investors own include SoFi Technologies (SOFI), Fluence Energy (FLNC), The9 (NCTY), Riot Platforms (RIOT), PubMatic (PUBM), Clean Energy Fuels (CLNE) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: www.synaptogen.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.28%
• Return on Assets: -58.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 72.59
• Quick Ratio: 72.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 1,352,000
• Market Cap: $11.68 million
• Optionable: Not Optionable
• Beta: 1.08